Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute

Dr. Schwartzberg on the Use of Myriad Genomic Testing in Cancer Care

June 30th 2022

Lee S. Schwartzberg, MD, FACP, discusses the utilization of genomics in cancer care.

Using Systemic Therapy to Treat HER2+ Breast Cancer

August 24th 2021

Closing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.

Emerging Therapies for HER2+ MBC

August 24th 2021

An overview of therapies under study in later-stage clinical trials to treat HER2-positive metastatic breast cancer.

Immunotherapy for HER2+ Breast Cancer

August 24th 2021

The rationale for incorporating checkpoint inhibitors into treatment regimens for HER2-positive breast cancer.

Emerging Combinations for Triple-Positive Breast Cancer

August 17th 2021

An overview of various trials investigating combination approaches as frontline therapy for triple-positive breast cancer and considerations for when to use chemotherapy and bring endocrine therapy into treatment.

Frontline Therapy for Triple-Positive Breast Cancer

August 17th 2021

Vijayakrishna Gadi, MD, PhD, defines triple-positive breast cancer and reacts to the potential use of trastuzumab combined with endocrine therapy as frontline therapy.

Gaps in Treatment for HER2+ MBC With Brain Metastasis

August 10th 2021

Considerations for addressing gaps in treatment for patients with HER2-positive metastatic breast cancer and brain metastasis, based on recent trial data.

Case Scenario: 55-Year-Old Woman With HER2+ MBC and Brain Metastasis

August 10th 2021

A discussion regarding the preferred treatment approach for a 55-year-old woman with HR-/HER2+ metastatic breast cancer and 2 brain metastases.

Treatment Options for HER2+ MBC With Brain Metastasis

August 3rd 2021

Options available to treat patients with HER2-positive metastatic breast cancer and brain metastasis, and factors that impact choice of therapy based on CNS data demonstrated in several clinical trials of HER2-targeted agents.

Brain Metastasis in HER2+ MBC

August 3rd 2021

Recommendations for screening patients with HER2-positive metastatic breast cancer for signs of brain metastasis as a consequence of current rates of prevalence.

Relapsed/Refractory HER2+ MBC Treatment Decisions

July 27th 2021

Options available to treat patients with HER2-positive metastatic breast cancer following frontline therapy with T-DM1.

Individualized Treatment Decisions for HER2+ Breast Cancer

July 27th 2021

Variables that breast oncologists need to consider when selecting an appropriate systemic treatment approach for a patient with HER2-positive breast cancer.

Subcutaneous Therapy for HER2+ Breast Cancer

July 20th 2021

Breast oncologists discuss the pros and cons of treating patients with HER2-postive breast cancer with the fixed-dose subcutaneous formulation of pertuzumab plus trastuzumab compared with IV chemotherapy.

Safety Profiles of Systemic Therapies for HER2+ MBC

July 20th 2021

Best practices for preventing and managing treatment-related adverse events associated with systemic therapies used to treat HER2-positive metastatic breast cancer.

Updates in HER2+ MBC: The NALA and SOPHIA Trials

July 13th 2021

Dr Lee Schwartzberg, MD, FASCO, highlights the appropriateness for treating HER2-positive metastatic breast cancer with either neratinib plus capecitabine or margetuximab plus chemotherapy based on evidence revealed by the NALA and SOPHIA clinical trials.

Implications of DESTINY-Breast01 in HER2+ MBC

July 13th 2021

Considerations for initiating trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who received previous treatment with trastuzumab emtansine based on data demonstrated by the DESTINY-Breast01 study.

The HER2CLIMB Study in HER2+ MBC

July 6th 2021

The significance of the HER2CLIMB study of tucatinib in combination with capecitabine and trastuzumab as treatment for patients with HER2-positive metastatic breast cancer.

Current Standard of Care for HER2+ MBC

July 6th 2021

Current treatment approaches available to treat HER2-positive metastatic breast cancer in the first- and second-line treatment settings.

Using Oral Therapies to Advance Care in MBC

February 16th 2021

Oral Therapies and Dose Reductions in MBC

February 16th 2021